JP2020521797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521797A5 JP2020521797A5 JP2019566199A JP2019566199A JP2020521797A5 JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5 JP 2019566199 A JP2019566199 A JP 2019566199A JP 2019566199 A JP2019566199 A JP 2019566199A JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- seq
- treatment
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174323.0 | 2017-06-02 | ||
| EP17174323 | 2017-06-02 | ||
| EP17196949.6 | 2017-10-17 | ||
| EP17196949 | 2017-10-17 | ||
| PCT/EP2018/064445 WO2018220169A1 (en) | 2017-06-02 | 2018-06-01 | Anti-cancer combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521797A JP2020521797A (ja) | 2020-07-27 |
| JP2020521797A5 true JP2020521797A5 (enExample) | 2021-07-26 |
Family
ID=62386492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566199A Pending JP2020521797A (ja) | 2017-06-02 | 2018-06-01 | 抗がん剤組み合わせ治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11198726B2 (enExample) |
| EP (1) | EP3630822A1 (enExample) |
| JP (1) | JP2020521797A (enExample) |
| KR (1) | KR20200013231A (enExample) |
| CN (1) | CN110691790A (enExample) |
| AU (1) | AU2018277227A1 (enExample) |
| BR (1) | BR112019022074A2 (enExample) |
| CA (1) | CA3061053A1 (enExample) |
| CL (1) | CL2019003430A1 (enExample) |
| IL (1) | IL270905A (enExample) |
| MX (1) | MX2019014199A (enExample) |
| PH (1) | PH12019502692A1 (enExample) |
| WO (1) | WO2018220169A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963175A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| AU2015345321A1 (en) * | 2014-11-10 | 2017-04-20 | F. Hoffmann-La Roche Ag | Anti-ANG2 antibodies and methods of use |
| CA3061053A1 (en) * | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| CA3195572A1 (en) | 2020-11-04 | 2022-05-12 | Heidelberg Pharma Research Gmbh | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
| WO2022194988A2 (en) | 2021-03-19 | 2022-09-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
| MX2024002962A (es) * | 2021-09-10 | 2024-05-17 | Soter Biopharma Pte Ltd | Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo. |
| EP4596579A1 (en) * | 2022-09-28 | 2025-08-06 | Kexing Biopharm Co., Ltd. | Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2 |
| US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
| KR20250152101A (ko) | 2023-03-13 | 2025-10-22 | 하이델베르크 파마 리서치 게엠베하 | 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체 |
| WO2025189977A1 (zh) * | 2024-03-13 | 2025-09-18 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2865464C (en) * | 2012-03-30 | 2022-07-12 | Boehringer Ingelheim International Gmbh | Ang2-binding molecules |
| CA2883880A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| BR112015006363A2 (pt) * | 2012-09-28 | 2017-08-08 | Boehringer Ingelheim Int | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| JP2018515450A (ja) | 2015-04-23 | 2018-06-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アンジオポイエチン２に結合する抗体のプログラムデスリガンド１に結合する抗体との併用療法 |
| WO2016170039A1 (en) * | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| CN109069638B (zh) * | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| UA127200C2 (uk) * | 2016-05-18 | 2023-06-07 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Молекула антитіла до pd1 |
| CA3061053A1 (en) * | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
-
2018
- 2018-06-01 CA CA3061053A patent/CA3061053A1/en active Pending
- 2018-06-01 MX MX2019014199A patent/MX2019014199A/es unknown
- 2018-06-01 KR KR1020197035427A patent/KR20200013231A/ko not_active Withdrawn
- 2018-06-01 US US15/995,375 patent/US11198726B2/en active Active
- 2018-06-01 EP EP18727819.7A patent/EP3630822A1/en not_active Ceased
- 2018-06-01 AU AU2018277227A patent/AU2018277227A1/en not_active Abandoned
- 2018-06-01 CN CN201880036511.5A patent/CN110691790A/zh active Pending
- 2018-06-01 JP JP2019566199A patent/JP2020521797A/ja active Pending
- 2018-06-01 WO PCT/EP2018/064445 patent/WO2018220169A1/en not_active Ceased
- 2018-06-01 BR BR112019022074-7A patent/BR112019022074A2/pt not_active IP Right Cessation
-
2019
- 2019-11-25 CL CL2019003430A patent/CL2019003430A1/es unknown
- 2019-11-25 IL IL270905A patent/IL270905A/en unknown
- 2019-11-28 PH PH12019502692A patent/PH12019502692A1/en unknown
-
2021
- 2021-11-08 US US17/520,748 patent/US20220340651A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024029009A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| CA2856646C (en) | Combination treatment of cancer | |
| JP2020518599A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2010270124A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| IL273169B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| IL288012B1 (en) | Antibody molecules against lag–3 and their use | |
| JP2006523216A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP7796663B2 (ja) | 過炎症性症候群の処置 | |
| JP2024516363A5 (enExample) | ||
| JP2019534003A5 (enExample) | ||
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| JP2018529661A5 (enExample) | ||
| TW201313228A (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| JP2023510199A5 (enExample) | ||
| JP2019534251A5 (enExample) | ||
| FI3565551T3 (fi) | Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 |